Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation

Molecular Cancer Research

Volumn 5, Issue 1, 2007, Pages 35-45

  DelloRusso, Christiana ^a   Welcsh, Piri L ^a   Wang, Weixin ^c   Garcia, Rochelle L ^a   King, Mary Claire ^a   Swisher, Elizabeth M ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CLAUDIN 6; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ARTICLE; CANCER CELL CULTURE; CANCER CLASSIFICATION; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONTROLLED STUDY; DNA DAMAGE; EXON; FUNCTIONAL ASSESSMENT; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; IONIZING RADIATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIATION DOSE; RADIOSENSITIVITY; UNINDEXED SEQUENCE;

BRCA1 PROTEIN; CARCINOMA, PAPILLARY; DNA DAMAGE; DNA REPAIR; DNA, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RADIATION, IONIZING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846976549     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-06-0234     Document Type: Article

References (67)

1. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-10.
2. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807-16.
3. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-89.
4. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
5. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11:63-70.
6. Connolly DC, Bao R, Nikitin AY, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63:1389-97.
7. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003;63:3459-63.
8. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002;1:53-62.
9. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002;108:171-82.
10. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet 2001;10:705-13.
11. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol Cancer Res 2005;3:531-9.
12. Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucleic Acids Res 2006;34:1416-26.
13. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-63.
14. Yuan Y, Kim WH, Han HS, et al. Establishment and characterization of human ovarian carcinoma cell lines. Gynecol Oncol 1997;66:378-87.
15. -/- epithelial ovarian cancers. Eur J Cancer 2006;42:1475-83.
16. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000;408:433-9.
17. Karagiannis TC, El-Osta A. Double-strand breaks: signaling pathways and repair mechanisms. Cell Mol Life Sci 2004;61:2137-47.
18. Shiloh Y. ATM and ATR: networking cellular responses to DNA damage. Curr Opin Genet Dev 2001;11:71-7.
19. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003;421:499-506.
20. Cortez D, Wang Y, Qin J, Elledge SJ. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 1999;286:1162-6.
21. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005;65:9603-6.
22. Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T. Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 gamma2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 2006;66:5251-7.
23. Scully R, Ganesan S, Vlasakova K, Chen J, Socolovsky M, Livingston DM. Genetic analysis of BRCA1 function in a defined tumor cell line. Mol Cell 1999;4:1093-9.
24. Wilson CA, Ramos L, Villasenor MR, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999;21:236-40.
25. Orban TI, Olah E. Emerging roles of BRCA1 alternative splicing. Mol Pathol 2003;56:191-7.
26. Wang H, Shao N, Ding QM, Cui J, Reddy ES, Rao VN. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. Oncogene 1997;15:143-57.
27. Thakur S, Zhang HB, Peng Y, et al. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. Mol Cell Biol 1997;17:444-52.
28. Scully R, Chen J, Ochs RL, et al. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997;90:425-35.
29. Zhang J, Willers H, Feng Z, et al. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. Mol Cell Biol 2004;24:708-18.
30. Hartwell LH, Weinert TA. Checkpoints: controls that ensure the order of cell cycle events. Science 1989;246:629-34.
31. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci U S A 1992;89:7491-5.
32. Xu B, Kim S, Kastan MB. Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 2001;21:3445-50.
33. Xu B, O'Donnell AH, Kim ST, Kastan MB. Phosphorylation of serine 1387 in Brca1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. Cancer Res 2002;62:4588-91.
34. Young BR, Painter RB. Radioresistant DNA synthesis and human genetic diseases. Hum Genet 1989;82:113-7.
35. 2 and mitosis. Cytometry 1998;32:71-7.
36. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev 2001;15:2177-96.
37. Wang Y, Cortez D, Yazdi P, Neff N, Elledge SJ, Qin J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev 2000;14:927-39.
38. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20:463-6.
39. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer 2003;97:2187-95.
40. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-5.
41. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis- diamminedichloroplatinum(II). Cancer Res 1998;58:1120-3.
42. Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 2000;275:23899-903.
43. Quinn JE, Kennedy RD, Mullan PB, et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
44. Cannistra SA. Cancer of the ovary. N Engl J Med 2004;351:2519-29.
45. Staff S, Nupponen NN, Borg A, Isola JJ, Tanner MM. Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ-line mutation carriers. Genes Chromosomes Cancer 2000;28:432-42.
46. Tomlinson GE, Chen TT, Stastny VA, et al. Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. Cancer Res 1998;58:3237-42.
47. Abbott DW, Thompson ME, Robinson-Benion C, Tomlinson G, Jensen RA, Holt JT. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J Biol Chem 1999;274:18808-12.
48. 2/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 2002;30:285-9.
49. 2-M cell cycle checkpoint. Cancer Res 2003;63:3049-53.
50. Yu X, Chini CC, He M, Mer G, Chen J. The BRCT domain is a phosphoprotein binding domain. Science 2003;302:639-42.
51. Zhong Q, Chen CF, Chen PL, Lee WH. BRCA1 facilitates microhomology- mediated end joining of DNA double strand breaks. J Biol Chem 2002;277:28641-7.
52. Merel P, Prieur A, Pfeiffer P, Delattre O. Absence of major defects in non-homologous DNA end joining in human breast cancer cell lines. Oncogene 2002;21:5654-9.
53. Bau DT, Fu YP, Chen ST, et al. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res 2004;64:5013-9.
54. Usami Y, Chiba H, Nakayama F, et al. Reduced expression of claudin-7 correlates with invasion and metastasis in squamous cell carcinoma of the esophagus. Hum Pathol 2006;37:569-77.
55. Nagaraja GM, Othman M, Fox BP, et al. Gene expression signatures and biomarkers of noninvasive and invasive breast cancer cells: comprehensive profiles by representational difference analysis, microarrays and proteomics. Oncogene 2006;25:2328-38.
56. Quan C, Lu SJ. Identification of genes preferentially expressed in mammary epithelial cells of Copenhagen rat using subtractive hybridization and microarrays. Carcinogenesis 2003;24:1593-9.
57. Ishikawa K, Nagase T, Nakajima D, et al. Prediction of the coding sequences of unidentified human genes. VIII. 78 new cDNA clones from brain which code for large proteins in vitro. DNA Res 1997;4:307-13.
58. Andrews HN, Mullan PB, McWilliams S, et al. BRCA1 regulates the interferon gamma-mediated apoptotic response. J Biol Chem 2002;277:26225-32.
59. Jazaeri AA, Yee CJ, Sotiriou C, Brantley KR, Boyd J, Liu ET. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J Natl Cancer Inst 2002;94:990-1000.
60. Yang Y, Lee JH, Kim KY, et al. The interferon-inducible 9-27 gene modulates the susceptibility to natural killer cells and the invasiveness of gastric cancer cells. Cancer Lett 2005;221:191-200.
61. Asefa B, Klarmann KD, Copeland NG, Gilbert DJ, Jenkins NA, Keller JR. The interferon-inducible p200 family of proteins: a perspective on their roles in cell cycle regulation and differentiation. Blood Cells Mol Dis 2004;32:155-67.
62. Sen GC. Novel functions of interferon-induced proteins. Semin Cancer Biol 2000;10:93-101.
63. Ziv Y, Bar-Shira A, Pecker I, et al. Recombinant ATM protein complements the cellular A-T phenotype. Oncogene 1997;15:159-67.
64. Nellemann C, Vinggaard AM, Dalgaard M, Hossaini A, Larsen JJ. Quantification of antiandrogen effect determined by Lightcycler technology. Toxicology 2001;163:29-38.
65. Schreiber E, Matthias P, Muller MM, Schaffner W. Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 1989;17:6419.
66. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 1989;60:65-71.
67. Jaspers NGJ, Zdzienicka MZ. Inhibition of DNA synthesis by ionizing radiation. In: Henderson DS, Henderson DS. DNA repair protocols: eukaryotic Systems. Totowa (NJ): Humana Press; 1999. p. 535-42.